REMINYL 16

New research on investigational Alzheimer's disease treatment suggests significant improvement o...( Reminyl's Dual Mode of Acti...)... Reminyl's Dual Mode of Action Provides Novel Approach f... 7 April 2000 Stockholm -- Results from a new five-month study cond... After 5 months patients who were treated with 16 mg/day and 24 mg/... Efficacy was measured using a variety of subscales including the Al... 7 April 2000, Stockholm -- Results from a new five-month study conducted by Janssen Research Foundation show that patients who were treated with Reminyl (galantamine), a new treatment for Alzheimer's disease showed a significant improvement in their cognitive, functional and behavioural symptoms, when measured by commonly-used assessments of the severity of Alzheimer's disease. The study is being presented today for the first time at the International Stockholm/Springfield Symposium, a meeting of leading experts to discuss advances in Alzheimer's therapy.